| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2022 | 775 | 2.600 |
Why?
|
| Pregnant Women | 6 | 2021 | 50 | 2.120 |
Why?
|
| Sexual Partners | 9 | 2021 | 105 | 2.010 |
Why?
|
| Prenatal Care | 4 | 2021 | 117 | 1.470 |
Why?
|
| Mass Screening | 9 | 2021 | 838 | 1.220 |
Why?
|
| Pregnancy | 25 | 2022 | 2334 | 1.140 |
Why?
|
| Sexual Behavior | 7 | 2016 | 179 | 1.010 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2017 | 71 | 0.940 |
Why?
|
| Sexually Transmitted Diseases | 6 | 2008 | 53 | 0.880 |
Why?
|
| Female | 68 | 2022 | 38021 | 0.820 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 51 | 0.810 |
Why?
|
| Maternal Health Services | 1 | 2021 | 22 | 0.760 |
Why?
|
| Psychometrics | 2 | 2021 | 514 | 0.730 |
Why?
|
| Young Adult | 25 | 2020 | 5710 | 0.730 |
Why?
|
| Reagent Kits, Diagnostic | 4 | 2020 | 54 | 0.670 |
Why?
|
| Patient Preference | 1 | 2019 | 57 | 0.670 |
Why?
|
| Self-Examination | 1 | 2018 | 6 | 0.660 |
Why?
|
| Adolescent | 22 | 2022 | 8904 | 0.660 |
Why?
|
| Humans | 75 | 2022 | 68549 | 0.650 |
Why?
|
| Adult | 40 | 2020 | 21379 | 0.640 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 73 | 0.640 |
Why?
|
| Family Health | 1 | 2018 | 83 | 0.630 |
Why?
|
| Quality of Health Care | 1 | 2021 | 322 | 0.620 |
Why?
|
| AIDS Serodiagnosis | 1 | 2018 | 17 | 0.620 |
Why?
|
| Papillomavirus Vaccines | 4 | 2022 | 82 | 0.600 |
Why?
|
| Substance-Related Disorders | 4 | 2018 | 1242 | 0.600 |
Why?
|
| Uganda | 7 | 2021 | 41 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 467 | 0.570 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2016 | 766 | 0.560 |
Why?
|
| Diabetes, Gestational | 3 | 2015 | 81 | 0.560 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 163 | 0.550 |
Why?
|
| Male | 41 | 2022 | 37283 | 0.540 |
Why?
|
| Birth Weight | 3 | 2013 | 186 | 0.540 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2014 | 285 | 0.520 |
Why?
|
| Weight Gain | 2 | 2013 | 135 | 0.510 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2016 | 17 | 0.480 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2016 | 22 | 0.480 |
Why?
|
| Risk Reduction Behavior | 2 | 2008 | 174 | 0.480 |
Why?
|
| Vagina | 3 | 2016 | 87 | 0.460 |
Why?
|
| Middle Aged | 25 | 2020 | 21119 | 0.460 |
Why?
|
| Pelvic Organ Prolapse | 2 | 2011 | 50 | 0.450 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2011 | 92 | 0.450 |
Why?
|
| Vaccination | 6 | 2022 | 182 | 0.440 |
Why?
|
| Tobacco Use | 1 | 2014 | 98 | 0.440 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 154 | 0.430 |
Why?
|
| Single Person | 1 | 2012 | 5 | 0.420 |
Why?
|
| Intrauterine Devices | 1 | 2012 | 15 | 0.410 |
Why?
|
| Contraceptive Agents, Female | 1 | 2012 | 16 | 0.410 |
Why?
|
| Premature Birth | 4 | 2021 | 150 | 0.410 |
Why?
|
| Contraception | 1 | 2012 | 27 | 0.410 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 132 | 0.400 |
Why?
|
| Uterine Cervicitis | 2 | 2014 | 18 | 0.390 |
Why?
|
| Substance Abuse Detection | 1 | 2011 | 66 | 0.390 |
Why?
|
| Public Sector | 1 | 2010 | 19 | 0.380 |
Why?
|
| Depression | 4 | 2019 | 942 | 0.380 |
Why?
|
| Body Weight | 1 | 2013 | 554 | 0.370 |
Why?
|
| Heterosexuality | 2 | 2020 | 16 | 0.360 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2010 | 92 | 0.360 |
Why?
|
| Intimate Partner Violence | 2 | 2021 | 58 | 0.350 |
Why?
|
| Postpartum Period | 1 | 2010 | 67 | 0.350 |
Why?
|
| Mexican Americans | 3 | 2008 | 30 | 0.350 |
Why?
|
| Adolescent Behavior | 2 | 2018 | 264 | 0.350 |
Why?
|
| Chlamydia Infections | 5 | 2016 | 41 | 0.350 |
Why?
|
| Pregnancy Complications | 2 | 2013 | 286 | 0.340 |
Why?
|
| Surveys and Questionnaires | 8 | 2021 | 2798 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 92 | 0.340 |
Why?
|
| Mycoplasma genitalium | 2 | 2006 | 4 | 0.340 |
Why?
|
| Body Mass Index | 1 | 2013 | 866 | 0.330 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 206 | 0.330 |
Why?
|
| Gonorrhea | 4 | 2022 | 50 | 0.330 |
Why?
|
| Methamphetamine | 1 | 2010 | 132 | 0.330 |
Why?
|
| Marriage | 2 | 2020 | 30 | 0.330 |
Why?
|
| Spouses | 2 | 2020 | 51 | 0.330 |
Why?
|
| Risk-Taking | 4 | 2018 | 210 | 0.330 |
Why?
|
| Logistic Models | 7 | 2012 | 1419 | 0.320 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2008 | 9 | 0.320 |
Why?
|
| Pelvic Inflammatory Disease | 2 | 2005 | 39 | 0.310 |
Why?
|
| Alkanesulfonic Acids | 2 | 2019 | 54 | 0.310 |
Why?
|
| Fetal Diseases | 1 | 2008 | 64 | 0.310 |
Why?
|
| Chlamydia trachomatis | 4 | 2016 | 26 | 0.310 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 955 | 0.300 |
Why?
|
| South Carolina | 10 | 2022 | 2752 | 0.300 |
Why?
|
| Fever | 1 | 2008 | 96 | 0.300 |
Why?
|
| Iran | 4 | 2021 | 12 | 0.300 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 378 | 0.300 |
Why?
|
| Fluorocarbons | 2 | 2019 | 82 | 0.300 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 848 | 0.300 |
Why?
|
| Smoking | 2 | 2014 | 1449 | 0.290 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 2265 | 0.290 |
Why?
|
| Environmental Monitoring | 2 | 2019 | 180 | 0.290 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.280 |
Why?
|
| Self Care | 2 | 2020 | 252 | 0.280 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 475 | 0.270 |
Why?
|
| Time Factors | 9 | 2019 | 4655 | 0.270 |
Why?
|
| Psychotic Disorders | 2 | 2018 | 157 | 0.270 |
Why?
|
| Mycoplasma Infections | 1 | 2006 | 40 | 0.270 |
Why?
|
| Health Personnel | 2 | 2022 | 286 | 0.260 |
Why?
|
| Spinal Cord Injuries | 3 | 2017 | 551 | 0.260 |
Why?
|
| Multivariate Analysis | 6 | 2016 | 1046 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 624 | 0.240 |
Why?
|
| Infant, Newborn | 7 | 2021 | 2455 | 0.230 |
Why?
|
| Serologic Tests | 2 | 2020 | 46 | 0.230 |
Why?
|
| Child Abuse | 1 | 2005 | 186 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2077 | 0.220 |
Why?
|
| Chlamydia | 1 | 2022 | 5 | 0.210 |
Why?
|
| Kenya | 2 | 2019 | 26 | 0.210 |
Why?
|
| Diphtheria | 1 | 2022 | 6 | 0.210 |
Why?
|
| Whooping Cough | 1 | 2022 | 8 | 0.210 |
Why?
|
| Tetanus | 1 | 2022 | 11 | 0.210 |
Why?
|
| Vaccines | 1 | 2022 | 21 | 0.210 |
Why?
|
| Ambulatory Care Facilities | 2 | 2019 | 91 | 0.210 |
Why?
|
| Sex Factors | 3 | 2017 | 1265 | 0.210 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2022 | 15 | 0.200 |
Why?
|
| Counseling | 3 | 2018 | 279 | 0.190 |
Why?
|
| Translations | 1 | 2021 | 12 | 0.190 |
Why?
|
| Sex Workers | 1 | 2021 | 9 | 0.190 |
Why?
|
| Body Composition | 2 | 2012 | 119 | 0.190 |
Why?
|
| N-Methylaspartate | 1 | 2021 | 59 | 0.190 |
Why?
|
| Maternal Age | 3 | 2020 | 70 | 0.190 |
Why?
|
| Prevalence | 4 | 2022 | 1609 | 0.190 |
Why?
|
| Spouse Abuse | 1 | 2020 | 40 | 0.180 |
Why?
|
| World Health Organization | 1 | 2020 | 53 | 0.180 |
Why?
|
| United States | 7 | 2019 | 7338 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2019 | 880 | 0.180 |
Why?
|
| Visitors to Patients | 1 | 2019 | 4 | 0.170 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 18 | 0.170 |
Why?
|
| Gestational Age | 4 | 2013 | 389 | 0.170 |
Why?
|
| Trichechus manatus | 1 | 2019 | 2 | 0.170 |
Why?
|
| Quality of Life | 3 | 2017 | 1515 | 0.170 |
Why?
|
| Risk Factors | 8 | 2018 | 5720 | 0.170 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 8 | 0.170 |
Why?
|
| Motor Cortex | 1 | 2021 | 158 | 0.170 |
Why?
|
| Alcohol Deterrents | 1 | 2019 | 86 | 0.170 |
Why?
|
| Delirium | 1 | 2019 | 45 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2019 | 93 | 0.160 |
Why?
|
| Rivers | 1 | 2019 | 43 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 3256 | 0.160 |
Why?
|
| Pneumococcal Infections | 1 | 2019 | 30 | 0.160 |
Why?
|
| Antibodies, Bacterial | 1 | 2019 | 90 | 0.160 |
Why?
|
| Family Characteristics | 1 | 2018 | 44 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 85 | 0.160 |
Why?
|
| Bullying | 1 | 2018 | 28 | 0.160 |
Why?
|
| Prodromal Symptoms | 1 | 2018 | 5 | 0.160 |
Why?
|
| Smegmamorpha | 1 | 2017 | 7 | 0.150 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 209 | 0.150 |
Why?
|
| Fertility | 1 | 2017 | 60 | 0.150 |
Why?
|
| Texas | 4 | 2005 | 92 | 0.150 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 72 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.150 |
Why?
|
| Rhode Island | 1 | 2017 | 9 | 0.150 |
Why?
|
| Family | 1 | 2019 | 293 | 0.150 |
Why?
|
| Aged | 9 | 2020 | 14842 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2019 | 344 | 0.140 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 30 | 0.140 |
Why?
|
| Birth Certificates | 2 | 2015 | 16 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 2 | 2012 | 504 | 0.140 |
Why?
|
| Dura Mater | 1 | 2016 | 23 | 0.140 |
Why?
|
| Mandatory Programs | 1 | 2016 | 8 | 0.140 |
Why?
|
| Students | 1 | 2018 | 233 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2011 | 448 | 0.140 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2016 | 29 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2019 | 335 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 257 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 805 | 0.130 |
Why?
|
| Hospitalization | 2 | 2019 | 977 | 0.130 |
Why?
|
| Crime Victims | 1 | 2018 | 286 | 0.130 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 447 | 0.130 |
Why?
|
| Water Pollutants, Chemical | 1 | 2019 | 328 | 0.120 |
Why?
|
| Electric Stimulation Therapy | 1 | 2016 | 147 | 0.120 |
Why?
|
| Asthma | 1 | 2018 | 345 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2015 | 249 | 0.120 |
Why?
|
| Phototherapy | 1 | 2014 | 28 | 0.120 |
Why?
|
| Pregnancy in Diabetics | 1 | 2015 | 70 | 0.120 |
Why?
|
| Age Factors | 3 | 2020 | 1860 | 0.120 |
Why?
|
| Sleep Deprivation | 1 | 2014 | 81 | 0.120 |
Why?
|
| Health Surveys | 2 | 2015 | 488 | 0.120 |
Why?
|
| Trichomonas vaginalis | 1 | 2014 | 22 | 0.120 |
Why?
|
| Alcoholism | 2 | 2019 | 1109 | 0.120 |
Why?
|
| Trichomonas Vaginitis | 1 | 2014 | 25 | 0.110 |
Why?
|
| Behavior Therapy | 2 | 2008 | 297 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1753 | 0.110 |
Why?
|
| Suicide | 1 | 2014 | 115 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2014 | 87 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 214 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 56 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1172 | 0.110 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2015 | 111 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2016 | 272 | 0.110 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 442 | 0.110 |
Why?
|
| Affect | 1 | 2014 | 218 | 0.110 |
Why?
|
| Motivation | 1 | 2017 | 561 | 0.110 |
Why?
|
| Influenza, Human | 1 | 2013 | 79 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2013 | 737 | 0.110 |
Why?
|
| Sleep | 1 | 2015 | 263 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2013 | 219 | 0.110 |
Why?
|
| Child | 4 | 2018 | 6401 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 3 | 2015 | 201 | 0.110 |
Why?
|
| Health Promotion | 2 | 2008 | 407 | 0.110 |
Why?
|
| Drug Implants | 1 | 2012 | 19 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7268 | 0.100 |
Why?
|
| Growth Charts | 1 | 2012 | 16 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2022 | 25 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2012 | 46 | 0.100 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2011 | 19 | 0.100 |
Why?
|
| Georgia | 2 | 2022 | 161 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2011 | 23 | 0.100 |
Why?
|
| Personality Inventory | 1 | 2012 | 197 | 0.100 |
Why?
|
| Impulsive Behavior | 1 | 2012 | 85 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 1 | 2016 | 402 | 0.100 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 47 | 0.100 |
Why?
|
| Gynecology | 1 | 2011 | 46 | 0.100 |
Why?
|
| Fetal Growth Retardation | 1 | 2011 | 56 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2011 | 219 | 0.090 |
Why?
|
| Classification | 1 | 2010 | 8 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.090 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 639 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 23 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 19 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2010 | 37 | 0.090 |
Why?
|
| Observer Variation | 1 | 2011 | 330 | 0.090 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2009 | 10 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4843 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2011 | 221 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 1026 | 0.090 |
Why?
|
| Pregnancy, Ectopic | 1 | 2009 | 16 | 0.090 |
Why?
|
| Incidence | 3 | 2022 | 1582 | 0.090 |
Why?
|
| Needlestick Injuries | 1 | 2009 | 10 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2005 | 1549 | 0.090 |
Why?
|
| Needles | 1 | 2009 | 34 | 0.090 |
Why?
|
| Methotrexate | 1 | 2009 | 91 | 0.090 |
Why?
|
| Attitude | 2 | 2022 | 121 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 125 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2009 | 101 | 0.080 |
Why?
|
| Family Practice | 1 | 2011 | 312 | 0.080 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2014 | 35 | 0.080 |
Why?
|
| Acidosis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 369 | 0.080 |
Why?
|
| Florida | 2 | 2019 | 221 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 492 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2016 | 2356 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 631 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 260 | 0.070 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2006 | 2 | 0.070 |
Why?
|
| Culture Techniques | 1 | 2006 | 65 | 0.070 |
Why?
|
| Medicaid | 1 | 2008 | 301 | 0.070 |
Why?
|
| Women's Health | 2 | 2004 | 148 | 0.070 |
Why?
|
| Safe Sex | 2 | 2003 | 24 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1074 | 0.070 |
Why?
|
| Brazil | 2 | 2019 | 48 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1085 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2018 | 369 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2022 | 307 | 0.060 |
Why?
|
| Psychology, Adolescent | 1 | 2005 | 38 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1174 | 0.060 |
Why?
|
| Software | 1 | 2007 | 418 | 0.060 |
Why?
|
| Pregnancy Outcome | 2 | 2019 | 157 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 772 | 0.060 |
Why?
|
| Least-Squares Analysis | 1 | 2004 | 35 | 0.060 |
Why?
|
| Battered Women | 1 | 2004 | 15 | 0.060 |
Why?
|
| Virginia | 2 | 2016 | 45 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 689 | 0.060 |
Why?
|
| Prognosis | 1 | 2009 | 2093 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 508 | 0.060 |
Why?
|
| Cervix Uteri | 1 | 2004 | 64 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 2891 | 0.060 |
Why?
|
| Minority Groups | 1 | 2005 | 196 | 0.060 |
Why?
|
| Physician's Role | 1 | 2003 | 116 | 0.050 |
Why?
|
| Sentinel Surveillance | 1 | 2022 | 20 | 0.050 |
Why?
|
| Decision Making | 2 | 2019 | 410 | 0.050 |
Why?
|
| Ethiopia | 1 | 2022 | 16 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 41 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2005 | 403 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2003 | 929 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2016 | 7028 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2004 | 502 | 0.050 |
Why?
|
| Sex Offenses | 1 | 2004 | 170 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 110 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 1341 | 0.050 |
Why?
|
| Poisson Distribution | 2 | 2011 | 84 | 0.050 |
Why?
|
| Evoked Potentials, Motor | 1 | 2021 | 63 | 0.050 |
Why?
|
| Social Stigma | 1 | 2021 | 53 | 0.050 |
Why?
|
| Gender Identity | 1 | 2020 | 47 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2016 | 392 | 0.050 |
Why?
|
| Comorbidity | 2 | 2018 | 1425 | 0.050 |
Why?
|
| Recurrence | 1 | 2002 | 948 | 0.040 |
Why?
|
| Disulfiram | 1 | 2019 | 22 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2019 | 95 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2002 | 424 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 24 | 0.040 |
Why?
|
| Population Groups | 1 | 2019 | 16 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 131 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 98 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2021 | 266 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2019 | 64 | 0.040 |
Why?
|
| Refugium | 1 | 2017 | 1 | 0.040 |
Why?
|
| Islands | 1 | 2017 | 3 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2019 | 222 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 1745 | 0.040 |
Why?
|
| Animals, Wild | 1 | 2017 | 18 | 0.040 |
Why?
|
| Naltrexone | 1 | 2019 | 195 | 0.040 |
Why?
|
| Psychological Trauma | 1 | 2018 | 32 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.040 |
Why?
|
| Viral Load | 1 | 2018 | 127 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 244 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 106 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2019 | 285 | 0.040 |
Why?
|
| Health Education | 1 | 2019 | 279 | 0.040 |
Why?
|
| Critical Care | 1 | 2019 | 263 | 0.040 |
Why?
|
| Epidural Space | 1 | 2016 | 15 | 0.040 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 413 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.030 |
Why?
|
| Anxiety | 1 | 2019 | 422 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2017 | 94 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 123 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2016 | 99 | 0.030 |
Why?
|
| Association Learning | 1 | 2015 | 36 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 521 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 866 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 374 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 782 | 0.030 |
Why?
|
| Vaginitis | 1 | 2014 | 21 | 0.030 |
Why?
|
| Tanzania | 1 | 2014 | 35 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2012 | 3703 | 0.030 |
Why?
|
| Coinfection | 1 | 2014 | 29 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 309 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2010 | 2004 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 208 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2015 | 418 | 0.030 |
Why?
|
| Plethysmography | 1 | 2012 | 17 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 188 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.030 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.030 |
Why?
|
| Fetal Weight | 1 | 2011 | 33 | 0.020 |
Why?
|
| Research Subjects | 1 | 2011 | 45 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2011 | 79 | 0.020 |
Why?
|
| Argentina | 1 | 2010 | 9 | 0.020 |
Why?
|
| Thailand | 1 | 2010 | 28 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 24 | 0.020 |
Why?
|
| Animals | 2 | 2019 | 20880 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2010 | 10 | 0.020 |
Why?
|
| Rural Population | 1 | 2014 | 397 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 88 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 81 | 0.020 |
Why?
|
| Gloves, Surgical | 1 | 2009 | 5 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 2009 | 68 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 439 | 0.020 |
Why?
|
| Case Management | 1 | 2008 | 46 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 500 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2007 | 66 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1465 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 503 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2008 | 383 | 0.020 |
Why?
|
| Trichomonas Infections | 1 | 2005 | 14 | 0.020 |
Why?
|
| Mexico | 1 | 2004 | 38 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 254 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 563 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 507 | 0.010 |
Why?
|